Packaging systems for human recombinant adenovirus to be used in gene therapy

• US 5,994,128 A
• Filed: 03/25/1997
• Issued: 11/30/1999
• Est. Priority Date: 06/15/1995
• Status: Expired due to Term

• Current Assignee: Crucell Holland B.V (Johnson & Johnson)
• Original Assignee: Introgene BV (Johnson & Johnson)
• Inventors: Valerio, Domenico, Van der Eb, Alex Jan, Bout, Abraham, Hoeben, Robert Cornelis, Fallaux, Frits Jacobus
• Primary Examiner(s): Campell, Bruce R.
• Assistant Examiner(s): Nguyen, Dave Trong
• Application Number:
  US08/793,170
• Time in Patent Office: 980 Days
• Field of Search: 435/172.3, 435/320.1, 435/325, 435/69.1, 435/455, 514/44, 424/93.21, 536/23.1, 935/51
• US Class Current: 435/325
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/10351 Methods of production or purification of viral material
• CPC Class Codes: C12N 2710/10352 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 2830/00 Vector systems having a special element relevant for transcription
• CPC Class Codes: C12N 2830/15 chimeric enhancer/promoter combination
• CPC Class Codes: C12N 2830/42 being an intron or intervening sequence for splicing and/or stability of RNA
• CPC Class Codes: C12N 2830/60 from viruses
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

Presented are ways to address the problem of replication competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector and are suited for large scale production of recombinant adenoviruses. A system for use with the invention produces adenovirus incapable of replicating. The system includes a primary cell containing a nucleic acid based on or derived from adenovirus and an isolated recombinant nucleic acid molecule for transfer into the primary cell. The isolated recombinant nucleic acid molecule is based on or derived from an adenovirus, and further has at least one functional encapsidating signal, and at least one functional Inverted Terminal Repeat. The isolated recombinant nucleic acid molecule lacks overlapping sequences with the nucleic acid of the cell. Otherwise, the overlapping sequences would enable homologous recombination leading to replication competent adenovirus in the primary cell into which the isolated recombinant nucleic acid molecule is to be transferred.

Claims

1. A system for producing adenovirus incapable of replicating, said system comprising:

a primary cell containing a nucleic acid encoding adenoviral E1A and E1B gene products, wherein aid nucleic acid lacks a gene coding for active or functional pIX; and

an isolated recombinant nucleic acid molecule for transfer into said primary cell, said isolated recombinant nucleic acid molecule based on or derived from an adenovirus of the family Adenoviridae, and further having

at least a functional encapsidating signal, and

at least one functional Inverted Terminal Repeat,

said isolated recombinant nucleic acid molecule lacking overlapping sequences with the nucleic acid of the cell, the overlapping sequences otherwise enabling homologous recombination leading to replication competent adenovirus in said primary cell into which said isolated recombinant nucleic acid molecule is to be transferred.

2. The system of claim 1 wherein said isolated recombinant nucleic acid molecule is in a linear form and comprises functional Inverted Terminal Repeats at or near both termini.

3. The system of claim 1 wherein said isolated recombinant nucleic acid molecule comprises a nucleic acid which alters the range of said adenovirus as compared to a wild-type adenovirus and wherein said primary cell is a non-human primary cell.

11. The producer cell according to claim 3 which is of monkey origin.

12. The system of claim 3 wherein said isolated recombinant nucleic acid molecule is DNA.

20. The system of claim 1 wherein said primary cell comprises a nucleic acid encoding a mutated E2 gene product which alters the host range of said adenovirus as compared to a wild-type adenovirus.

4. An adenoviral producer cell that does not produce replication competent adenovirus, said adenoviral producer cell comprising:

one or more recombinant nucleic acid molecules having no overlapping sequences with respect to one another which would otherwise allow for homologous recombination leading to replication competent adenovirus in said adenoviral producer cell, and wherein said adenoviral producer cell comprises a nucleic acid encoding adenoviral E1A and E1B gene products, said nucleic acid lacking a gene coding for functional or active pIX.

7. The producer cell according to claim 4, wherein any one or more of said recombinant nucleic acid molecules thereof further comprises a marker gene.

8. The producer cell according to claim 7, wherein the marker gene is under control of an E1A adenoviral gene product responsive promoter.

9. The producer cell according to claim 4 or 5, which is a diploid cell.

10. The producer cell according to claim 4 or 5, which is of non-human origin.

13. The adenoviral producer cell of claim 4 or 5 wherein at least one of said one or more recombinant nucleic acid molecules comprises at least one functional encapsidating signal and one functional Inverted Terminal Repeat, but lacks nucleotides 459-3510 of the E1 gene of adenovirus.

14. The adenoviral producer cell of claim 4 or 5 wherein at least one of said one or more recombinant nucleic acid molecules comprises at least one functional encapsidating signal and one functional Inverted Terminal Repeat, but lacks nucleotides 459-1713 of the E1 gene of adenovirus.

15. The producer cell according to claim 4 wherein a recombinant nucleic acid molecule thereof further comprises a mutated E2A adenoviral gene that encodes a temperature sensitive gene product.

5. An adenoviral producer cell that does not produce replication competent adenovirus, said adenoviral producer cell comprising:

one or more recombinant nucleic acid molecules having no overlapping sequences with respect to one another which would otherwise allow for homologous recombination leading to replication competent adenovirus in said adenoviral producer cell, and wherein said adenoviral producer cell comprises a nucleic acid encoding adenoviral E1 and E1B gene products, said nucleic acid lacking a gene coding for functional or active pIX, and E2A gene product under the control of an inducible promoter.

6. An adenoviral producer cell that does not produce replication competent adenovirus, said adenoviral producer cell comprising:

one or more recombinant nucleic acid molecules having no overlapping sequences with respect to one another which would otherwise allow for homologous recombination leading to replication competent adenovirus in said adenoviral producer cell, said adenoviral producer cell comprises a nucleic acid encoding adenoviral E1 and E2A gene products, said nucleic acid lacking a gene coding for functional or active pIX, and wherein said E2A gene product encodes a temperature sensitive mutation.

19. The producer cell of claim 6 wherein said E2A gene product is under the control of an inducible promoter.

16. An established adenoviral producer cell that lacks a gene encoding for active or functional pIX and does not produce replication competent adenovirus, said established adenoviral producer cell derived from a primary cell, said established adenoviral producer cell comprising:

one or more recombinant nucleic acid molecules having no overlapping sequences within each of the recombinant nucleic acid molecules, wherein said adenoviral producer cell comprises DNA sequences encoding functional adenoviral E1A and E1B gene products.

17. The established adenoviral producer cell of claim 16 wherein at least one of said one or more recombinant nucleic acid molecules further comprises DNA sequences encoding an adenoviral E2A gene product.

18. The established adenoviral producer cell of claim 16 wherein said DNA sequence encoding an adenoviral E2A gene product is selected from the group consisting of a DNA sequence encoding the wild-type E2A gene operably linked to an inducible promoter and a DNA sequence encoding a temperature sensitive 125 mutation.